Search 

Arecor has a proprietary and patented technology platform for improving the stability of a range of therapeutic proteins including vaccines, monoclonal antibodies, peptides, blood factors and fusion proteins

The Communications Strategy Group Inc. is US-based consultancy providing corporate/financial communications and business development services to the life sciences, biotech and medical technology sectors; assist and advise UK and EU companies seeking to expand to the US; corporate mentoring; assets partnering; capital formation.

The Communications Strategy Group Inc. acts as a contact point for UK companies attending US conferences, in partnership with Biopartner.co.uk, a UK Accredited Trade Organisation facilitating international partnering for trade, investment and collaborations with Life Sciences organisations across the UK. BioPartner is a membership organisation, supporting UK SMEs and startups, and signposting organisations worldwide to UK expertise.

Biopartner.co.uk has alliances with organisers of international biopartnering events, and with UK membership organisations, operating both independently and in partnership with the UK government. BioPartner disseminates tradeshow access grants to help UK-based SMEs exhibit their services and products in new overseas markets.

Domainex is a drug discovery company with a reputation for speed and innovation built on an exceptional track record of drug candidate delivery. It has a world class discovery team with an unrivalled track record and three client drug candidates

Haemostatix has developed a new class of peptide-based haemostat for the treatment of bleeding. The technology is based on a peptide that binds to the blood protein fibrinogen, inducing the rapid and targeted formation of clots.

IMS offers magnetic antibodies and adaptor proteins to the life science community (research and bioprocessing) while further developing the technology platform for licensing and partnering opportunities in medicine (diagnostics and therapeutics).

IBML, through its associate companies, OctaPhillip Bioscience Managers Ltd and Union MedTech PLC, specialises in investment in life science and medical technology companies.

Kymab is a biopharmaceutical company engaged in the discovery and development of human monoclonal antibody therapeutics.

PolyTherics is a biotechnology company that offers a comprehensive range of site-specific conjugation technologies and polymer-based technologies which are being applied to the development and enhancement of biologicals and other therapeutic entities.

Prosonix is a speciality pharmaceutical company developing a portfolio of inhaled respiratory medicines enabled by its state-of-the-art particle engineering technology.

ReNeuron is a leading, clinical-stage stem cell business. Its primary objective is the development of novel stem cell therapies targeting areas of significant unmet or poorly met medical need.